SCHEMBL3237278

SCHEMBL3237278

Cc1[nH]nc2c(NCc3ccco3)ncnc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 2/20 0.72
CDK1 P06493 2/20 0.72
CCNB1 P14635 2/20 0.72
CCNB3 Q8WWL7 2/20 0.72
POLB P06746 4/20 0.55
SMN1; SMN2 Q16637 9/20 0.55
HTT P42858 6/20 0.55
MAPK1 P28482 5/20 0.55
TSHR P16473 5/20 0.55
ALDH1A1 P00352 5/20 0.55
LMNA P02545 5/20 0.55
HPGD P15428 5/20 0.55
MAPT P10636 4/20 0.55
KDM4E B2RXH2 4/20 0.55
HSD17B10 Q99714 3/20 0.55
USP2 O75604 1/20 0.55
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
PKM P14618 1/20 0.53
ALOX15 P16050 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3239134 0.84 CCNB2 (1.00) CCNB2CDK1CCNB1CCNB3POLB
SCHEMBL3237285 0.81 CCNB2 (0.61) CCNB2CDK1CCNB1CCNB3POLB
SCHEMBL17009464 0.77 CCNB2 (0.56) CCNB2CDK1CCNB1CCNB3POLB
SCHEMBL3239140 0.77 CCNB2 (0.68) CCNB2CDK1CCNB1CCNB3POLB
Kinetin SCHEMBL29829493 0.75 SMN1; SMN2 (0.66) CCNB2CDK1CCNB1CCNB3POLB
Kinetin SCHEMBL15705 0.75 SMN1; SMN2 (0.66) CCNB2CDK1CCNB1CCNB3POLB
SCHEMBL11105662 0.73 SMN1; SMN2 (0.60) CCNB2CDK1CCNB1CCNB3POLB
SCHEMBL11110949 0.73 SMN1; SMN2 (0.59) CCNB2CDK1CCNB1CCNB3POLB
SCHEMBL14779321 0.73 SMN1; SMN2 (0.56) CCNB2CDK1CCNB1CCNB3POLB
SCHEMBL14780041 0.72 SMN1; SMN2 (0.55) CCNB2CDK1CCNB1CCNB3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1475094-B1 Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use USTAV EX BOTAN AKADEMIE VED CE (CZ) 2010-07-28 EP disclosed
US-20070167466-A1 \"Pyrazolo [4,3-d]pyrimidines, processes for their preparation and methods of use\ UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2007-07-19 US disclosed
WO-2004098608-A1 PYRAZOLO [4, 3-D]PYRIMIDINES, PROCESSES FOR THEIR PREPARATION AND METHODS OF USE ÚSTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2004-11-18 WO disclosed
EP-1475094-A1 Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167466-A1 \"Pyrazolo [4,3-d]pyrimidines, processes for their preparation and methods of use\ CBR3, PYM1, PNPO CCNB2 1222/4885CDK1 1025/4885CCNB1 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.